Claims
- 1. A biomass for producing virus/virus antigen, comprising cell aggregates of avian embryo cells, wherein said cell aggregates have diameters of between 100 .mu.m and 1,000 .mu.m and have been infected with a virus.
- 2. The biomass of claim 1, wherein the cell aggregates are obtained by mechanical and enzymatic treatment of avian embryo tissue.
- 3. The biomass of claim 1, wherein the cell aggregates are obtained by treating single cells of avian embryos with cell aggregating substances.
- 4. The biomass of claim 1, wherein the biomass has a metabolic activity based on glucose consumption of between 3 and 5 mg of glucose consumption per gram of biomass per hour when said biomass is suspended in culture medium.
- 5. The biomass of claim 1, wherein said avian embryo cells are chick embryo cells.
- 6. The biomass of claim 1, wherein said virus is selected from the group consisting of influenza, vaccinia and avipox.
- 7. The biomass of claim 6, wherein said virus is influenza.
- 8. The biomass of claim 6, wherein said virus is vaccinia.
- 9. The biomass of claim 6, wherein said virus is avipox.
- 10. A method of producing virus/virus antigen comprising:
- (a) infecting a biomass comprised of cell aggregates of avian embryo cells, wherein said cell aggregates have diameters of between 100 .mu.m and 1,000 .mu.m, with a virus in a culture medium having an oxygen concentration of at least 0.01 mmol/l;
- (b) producing a cell aggregate mixture containing virus/virus antigen; and
- (c) recovering said virus/virus antigen from the cell aggregate mixture.
- 11. The method of claim 10, wherein said avian embryo cells are chick embryo cells.
- 12. The method of claim 10, wherein an oxygen transfer rate of more than 1.60 mmol O.sub.2 .multidot.l.sup.-1 .multidot.h.sup.-1 is maintained in said culture medium.
- 13. The method of claim 12, wherein said oxygen transfer rate is between 1.65 and 2.40 mmol O.sub.2 .multidot.l.sup.-1 .multidot.h.sup.-1.
- 14. The method of claim 10, wherein said culture medium contains at least 10 mg of cell aggregates per ml.
- 15. The method of claim 10, wherein said culture medium has an oxygen concentration of at least 0.06 mmol/l.
- 16. The method of claim 10, wherein said virus is selected from the group consisting of influenza, vaccinia and avipox.
- 17. The method of claim 16, wherein said virus is influenza.
- 18. The method of claim 16, wherein said virus is vaccinia.
- 19. The method of claim 16, wherein said virus is avipox.
Priority Claims (1)
Number |
Date |
Country |
Kind |
18/90 |
Jan 1990 |
AUX |
|
Parent Case Info
This application is a continuation of U.S. Ser. No. 07/854,630, filed Jul. 6, 1992, now U.S. Pat. No. 5,391,491, which is a .sctn.371 application of PCT/AT91/00003, filed Jan. 3, 1991.
US Referenced Citations (5)
Foreign Referenced Citations (3)
Number |
Date |
Country |
358167 |
Aug 1980 |
AUX |
2444466 |
Jul 1980 |
FRX |
190919 |
Jan 1990 |
HUX |
Non-Patent Literature Citations (2)
Entry |
Slavik et al., "Optimalized Conditions of Tick-borne Encephalitis Virus Production in vitro", Acta Virologica, vol. 27, Mar. 1983. |
Samuel et al., Rev. Roum. Med.-Virol., 32 (2): 145-54 (1981). |
Continuations (1)
|
Number |
Date |
Country |
Parent |
854630 |
Jul 1992 |
|